Special Advisor s/ CHARXXXXX XXXXXX-XXXXX ---------------------------------- Charxxxxx Xxxxxx-Xxxxx
Special Advisor. From and after the Effective Date and until the Retirement Date (or, if earlier, the Date of Termination of the Executive’s employment in accordance with Section 6 of this Agreement), the Executive shall continue employment with the Company in the position of a Special Advisor. In such capacity, the Executive shall report directly to the Board and, to the extent requested by the Board, shall advise and assist the Chief Executive Officer of the Company and other senior executives of the Company on matters relating to the operation and strategic initiatives of the Company, and shall have such other duties and responsibilities as the Board may specify from time to time. The Executive shall, unless his services are earlier terminated pursuant to Section 6 of the Agreement, be deemed to retire from all positions of any kind with the Company and its subsidiaries and affiliates on the Retirement Date, and such retirement shall be automatic and without any further action on the part of the Company or the Executive, and the Executive shall execute such other documentation with respect thereto as reasonably requested by the Company.
Special Advisor. LICENSEE will retain LICENSOR for the term of this --------------- Agreement as a Special Advisor to LICENSEE, for an annual retainer of [the confidential material contained herein has been omitted and has been separately filed with the Commission] paid quarterly on the first day of the second month of each quarter. The first quarter payment shall be payable on a pro-rata basis. LICENSEE and LICENSOR will execute a confidentiality agreement, attached as Exhibit B, as a part of this arrangement. It is expected that LICENSEE will have regular meetings with LICENSOR at which time progress on the development of products, etc. relating to LICENSOR's technology will be presented to LICENSOR. Reasonable expenses relating to LICENSOR's travel in connection with meetings that LICENSEE requests LICENSOR attend, will be reimbursed upon submission of a written invoice and copies of all receipts therefor. In addition, new ideas or suggestions that LICENSOR may have regarding LICENSEE's existing or proposed projects may be discussed at these meetings. [the confidential material contained herein has been omitted and has been separately filed with the Commission]. However, such LICENSOR's consulting services shall be limited to a maximum of ten (10) days per year. Consulting services requiring travel by LICENSOR shall be limited to no more than [the confidential material contained herein has been omitted and has been separately filed with the Commission] trips per year with a maximum of [the confidential material contained herein has been omitted and has been separately filed with the Commission] per month and no more than [the confidential material contained herein has been omitted and has beenseparately filed with the Commission] days per trip. Additional consulting services shall be provided by LICENSOR only upon LICENSOR's approval.
Special Advisor. Rubicon shall appoint MxXxxx as a special advisor to Rubicon for a period of two years from the Closing Date, and MxXxxx will accept such appointment.
Special Advisor. From and between the Separation Date and January 19, 2023 (the “Advisory Term”), Employee shall serve as a special advisor to the board of directors of the Company (the “Board”) and shall make himself available upon a reasonable basis to the Board and the Chairman of the Board. Employee and the Company agree that Employee will not be an employee of the Company during the Advisory Term. The Non-Disclosure Agreement shall continue to apply during the Advisory Term and the “Restricted Period” under the Non-Competition Agreement shall include the duration of the Employee’s employment with the Company, the Advisory Term and the twelve (12) month period thereafter.
Special Advisor. The Special Advisor and the Successor Special Advisor Group shall consist of the Financial Advisor (who shall only vote as specifically set forth herein) and the Active Business Advisory Group.
Special Advisor. 5.1 With effect from the expiry of the Initial Period the Executive shall be appointed to the role of Special Advisor.
5.2 The Executive’s appointment as Special Advisor shall be for a limited term, to expire on the second anniversary of the Effective Date.
5.3 As Special Advisor the Executive will have the following duties, in addition to the general duties recorded in Clause 2 of the Employment Contract:
(a) Assisting with and supporting the integration of the Company and its Subsidiaries (together “NEX”) business with that of CME and the combined group’s cost synergy efforts;
(b) Assisting with the continued evolution of the NEX businesses;
(c) Assisting with and supporting engagement with customers in Europe, the Middle East and Asia; and
(d) Any other duties reasonably assigned to the Executive by CME related to the NEX businesses.
Special Advisor. On or before December 31, 2001, (i) you may elect to voluntarily resign from your position(s) described in Section 1(a) or (ii) the Company may remove you from such positions, and from the date of such resignation or removal (the "Transition Date") through the one (1) year anniversary of the Transition Date (the "End Date"), you will serve as a Special Advisor to the Company, with your salary and bonus compensation as described in Section 6 (a) hereof. As of the Transition Date, if any, you will resign as President and Chief Executive Officer of MyCIX.xxx xx from such other executive positions you accepted as described in Section 1(a) and, although you will remain an employee of the Company through the End Date in your role as Special Advisor, you will relinquish all other officer and director positions with the Company and its affiliates. As a Special Advisor, you will render such business and professional services in the performance of your duties, consistent with your position within the Company, as shall reasonably be agreed upon by you and the Board or CEO. As a Special Advisor, you will no longer be considered an officer for purposes of Section 16 of the Securities Act of 1934, as amended. Additionally, you will no longer be subject to the insixxx xxxxxxx xxxicies of the Company or its affiliated entities and shall not be subject to any pre-clearance requirements or trading windows for the purchase or sale of the stock of the Company or its affiliated entities.
(i) After the Transition Date, you may, subject to Sections 10, 11, and 12, engage in any other employment or consulting activities for any other entity or person whatsoever. In the event you obtain alternative employment with an employer other than the Company or any of its affiliates at any time prior to the End Date, your role with the Company shall either be governed by this Agreement, or, if mutually agreed upon in writing between you and the Company, by terms which may include, among other things, your change in status from an employee to consultant. Absent Cause for terminating your employment (as defined in Section 6), and subject to your continued compliance with the terms of this Agreement, the Company agrees to use its best faith efforts to ensure that you will continue to be an employee, or to otherwise provide consulting or advisory services to the Company, through the End Date.
Special Advisor. From November 1, 2019 through December 31, 2020 (the “End Date”), you will be employed by the Company as a Special Advisor, reporting to the Chief Executive Officer (the period in which you provide services as a Special Advisor, the “Advisory Period”). During the first two months of the Advisory Period, you will assist in the transition of your operational and management responsibilities to the new president of Xxxxx’x Analytics and thereafter, you will be available to perform such duties as are reasonably assigned to you, consistent with your skills and experience, by the Chief Executive Officer from time to time, which may include, but are not limited to, advising and assisting the Company in its strategic plans relating to product portfolios, product development, customer retention and other transition matters in the risk analytics space.
Special Advisor. Xx. Xxxxxxxxx is a Professor and Board of Governors Research Chair in Epigenetics at the University of Lethbridge. He is an expert in plant biotechnology, with focus on medicinal plants such as cannabis and poppy, breeding, epigenetics, epigenomics, bioinformatics, genetic engineering and next generation sequencing (NGS) applications. Since 2001, Xx. Xxxx Xxxxxxxxx has led a research group, working in various areas of plant biotechnology and genetic engineering. He has published over 150 peer- reviewed articles, numerous books and abstracts and obtained 10 patents. He was instrumental in breeding a special variety of medicinal poppy – thebaine poppy for which he has received an ASTech Award for the Innovation in Agricultural Sciences. In 2015, Xx. Xxxxxxxxx together with his business partner Xx. Xxxxxx Xxxxxx, started two other companies, InPlanta Biotechnology and Pathway Rx focusing on cannabis breeding and personalized medical cannabis approach, respectively. Since that time, InPlanta Biotechnology became a leader in breeding cannabis, creating hundreds of new cannabis hybrids and developed multiple innovative techniques for genomics-assisted cannabis breeding. InPlanta holds hemp breeding license and is currently registering several new hemp varieties.
